学术周报 · IF≥10
胆胰外科领域文献阅读汇编
2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer letters | 5 | IF 11.8 |
| Journal of hematology & oncology | 2 | IF 47.8 |
| ACS sensors | 2 | IF 10.9 |
| Nature cancer | 1 | IF 28.0 |
| Cancer cell | 1 | IF 56.1 |
| Cancer research | 1 | IF 22.6 |
| Endoscopy | 1 | IF 11.8 |
| Cellular & molecular immunology | 1 | IF 23.9 |
| Annals of internal medicine | 1 | IF 17.2 |
| Experimental hematology & oncology | 1 | IF 17.5 |
1胰腺癌 (10篇)
临床研究 (2篇)
Pancreatic ductal adenocarcinoma (PDAC) is a near-universally lethal malignancy, with KRAS mutations driving tumorigenesis in over 90% of cases. For decades considered undruggable, oncogenic KRAS has now been therapeutically engaged across multiple mutational subtypes, a revolution precipitated by allele-specific covalent inhibitors and accelerated by the emergence of RAS(ON) multi-selective inhibitors. The pivotal phase 3 RASolute 302 trial of daraxonrasib, a pan-RAS(ON) inhibitor, demonstrated nearly doubled median overall survival (13.2 versus 6.7 months; HR 0.40; P < 0.0001) over standard chemotherapy in previously treated metastatic PDAC. Concurrently, mutation-selective G12D inhibitors (zoldonrasib, VS-7375, INCB161734), G12D-targeted protein degraders (setidegrasib), G12C-selective RAS(ON) compounds (elironrasib), and next-generation MEK inhibitors (atebimetinib) are advancing through clinical evaluation. This review synthesizes the biological basis of KRAS-driven oncogenesis in the pancreas, the mutational landscape and its prognostic implications, the structural and mechanistic evolution of KRAS inhibitor classes, contemporary and emerging clinical data from recent trials, toxicity profiles and their management, and resistance mechanisms. The field stands at an inflection point: daraxonrasib now redefines second-line PDAC management, while first-line combination regimens with daraxonrasib plus chemotherapy have produced an ORR of 58% in early-phase single-arm data, a result now being tested in the randomized RASolute 303 trial. The challenge ahead lies in translating these results into durable remissions through rational combination therapy and in overcoming acquired resistance.
中文摘要:胰腺导管腺癌(PDAC)是一种几乎普遍致死的恶性肿瘤,超过90%的病例由KRAS突变驱动肿瘤发生。数十年来被视为不可成药的致癌KRAS,如今已在多种突变亚型上实现治疗性干预,这一转变由等位基因特异性共价抑制剂引发,并因RAS(ON)多选择性抑制剂的问世而加速。泛RAS(ON)抑制剂daraxonrasib的关键3期RASolute 302试验显示,在既往接受过治疗的转移性PDAC患者中,其中位总生存期较标准化疗几乎翻倍(13.2个月对6.7个月;HR 0.40;P < 0.0001)。与此同时,突变选择性G12D抑制剂(zoldonrasib、VS-7375、INCB161734)、靶向G12D的蛋白降解剂(setidegrasib)、G12C选择性RAS(ON)化合物(elironrasib)以及新一代MEK抑制剂(atebimetinib)正推进临床评估。本综述整合了胰腺中KRAS驱动致癌的生物学基础、突变图谱及其预后意义、KRAS抑制剂类别在结构与机制上的演进、近期试验的当代与新兴临床数据、毒性特征及其管理,以及耐药机制。该领域正处于转折点:daraxonrasib重新定义了PDAC二线治疗,而daraxonrasib联合化疗的一线方案在早期单臂数据中客观缓解率达58%,该结果正在随机对照的RASolute 303试验中接受验证。未来的挑战在于通过合理的联合治疗将这些结果转化为持久缓解,并克服获得性耐药。
Early diagnosis and accurate staging are essential for improving treatment efficacy and clinical outcomes of pancreatic cancer (PC), but remain challenging because of limited early PC-specific biomarkers and high-performance detection methods. In this paper, we developed a machine learning (ML)-enhanced terahertz (THz)-colorimetric dual-mode metadevice based on metallic nanonetworks for multiplexed microRNA (miRNA) detection and early PC diagnosis. Clinical sample measurements and bioinformatics analysis identified miRNA-21, miRNA-1290, and miRNA-320a as candidate PC biomarkers. Target miRNAs triggered the assembly of DNA-functionalized Fe and Au nanoparticles (NPs) with PEI-modified CuS NPs into ternary Fe/Au/Cu nanonetworks, generating THz and colorimetric signals through their dielectric and peroxidase-like properties. This target-triggered assembly enabled three-miRNA panel analysis without enzyme-mediated nucleic acid amplification and achieved attomolar-level miRNA profiling. Six ML algorithms were integrated to develop predictive models for PC diagnosis and staging. Linear discriminant analysis (LDA) achieved diagnostic accuracies of 97.8% (95% CI: 88.2-99.9%) in the training cohort (n = 45) and 96.7% (95% CI: 82.8-99.9%) in the validation cohort (n = 30), with 100% sensitivity for early PC in both cohorts. Compared with CA19-9, CA125, and CEA, the multiplexed miRNA-based dual-mode metadevice showed higher efficacy (area under the curve, AUC: 1.00 vs 0.905), supporting its potential for clinical miRNA-based liquid biopsy.
中文摘要:胰腺癌(PC)的早期诊断和准确分期对提高治疗效果和临床结局至关重要,但受限于早期PC特异性生物标志物不足和高性能检测方法缺乏,仍面临挑战。研究开发了一种基于金属纳米网络、机器学习(ML)增强的太赫兹(THz)-比色双模式超材料器件,用于多重microRNA(miRNA)检测和PC早期诊断。临床样本检测和生物信息学分析确定miRNA-21、miRNA-1290和miRNA-320a为候选PC生物标志物。靶标miRNA触发DNA功能化Fe和Au纳米颗粒(NPs)与PEI修饰CuS NPs组装成三元Fe/Au/Cu纳米网络,借助其介电特性和类过氧化物酶特性产生THz和比色信号。这种靶标触发组装无需酶介导的核酸扩增即可实现三-miRNA组合分析,并达到阿摩尔级miRNA谱分析。整合六种ML算法建立PC诊断和分期预测模型。线性判别分析(LDA)在训练队列(n = 45)中诊断准确率为97.8%(95% CI:88.2-99.9%),在验证队列(n = 30)中为96.7%(95% CI:82.8-99.9%),两个队列对早期PC的敏感性均为100%。与CA19-9、CA125和CEA相比,基于多重miRNA的双模式超材料器件表现出更高效能(曲线下面积,AUC:1.00 vs 0.905),支持其用于临床基于miRNA的液体活检的潜力。
基础研究 (8篇)
In pancreatic ductal adenocarcinoma (PDAC), the fibroblastic stroma constitutes most of the tumor mass and is remarkably devoid of functional blood vessels, leaving unresolved how PDAC cells obtain essential metabolites and water-insoluble lipids. We find that cancer-associated fibroblasts (CAFs) acquire and transfer lipids from blood-borne particles to PDAC cells through trogocytosis of CAF plasma membranes, a process requiring the CAF-expressed phospholipid scramblase anoctamin 6 (ANO6) to promote PDAC cell survival. Cancer cells and CAFs form synapse-like contacts that induce cytosolic calcium influx in CAFs through Orai channels, activating ANO6 and driving phosphatidylserine exposure on CAF membranes, which initiates trogocytosis and transfer of membrane lipids, including cholesterol, to PDAC cells. This ANO6-dependent phosphatidylserine externalization also supports CAF-mediated immunosuppression of cytotoxic T cells through trogocytosis. Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.
中文摘要:在胰腺导管腺癌(PDAC)中,纤维母细胞性间质构成肿瘤大部分,且明显缺乏功能性血管,PDAC细胞如何获得必需代谢物和水不溶性脂质仍未明确。我们发现CAF通过对CAF质膜的胞啃作用,从血源性颗粒获取脂质并转移给PDAC细胞;该过程需要CAF表达的磷脂加扰酶anoctamin 6(ANO6)来促进PDAC细胞存活。癌细胞与CAF形成突触样接触,经Orai通道诱导CAF胞质钙内流,激活ANO6并驱动CAF膜上磷脂酰丝氨酸外露,从而启动胞啃作用并将包括胆固醇在内的膜脂转移至PDAC细胞。这种ANO6依赖的磷脂酰丝氨酸外露也通过胞啃作用支持CAF介导的对细胞毒性T细胞的免疫抑制。阻断ANO6可拮抗肿瘤生长,部分通过破坏胆固醇向癌细胞的递送,并减弱免疫抑制,表明ANO6是PDAC的候选治疗靶点。
KRASG12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRASG12D-targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRASG12D-mutant subset intrinsically resistant to KRASG12D-targeted therapeutics, characterized by marked downregulation of innate immune signaling pathways. Functional validation demonstrates that suppressing interferon signaling in sensitive models induces resistance, whereas activation of interferon signaling, particularly interferon beta (IFN-β), increases sensitivity in resistant models. Combining IFN-β with KRAS inhibitors (MRTX1133, HRS-4642, and RMC-6236) exhibits synergistic antitumor effects in intrinsically resistant pancreatic cancer. Mechanistically, sustained MYC activity is associated with attenuated sensitivity to KRAS inhibition and correlates with repressed interferon signaling, suggesting a potential role in promoting intrinsic resistance. These findings identify interferon signaling as a candidate determinant of KRAS-targeted therapy response and support interferon-based combinations as a potential strategy for intrinsically resistant pancreatic cancer.
中文摘要:KRASG12D 是胰腺癌的主要驱动因素,但 KRASG12D 靶向治疗的内在耐药基础仍不明确。对 242 例患者来源类器官(PDO)及配对肿瘤组织进行基因组学、转录组学和蛋白质组学整合分析,识别出一个对 KRASG12D 靶向药物内在耐药的 KRASG12D 突变亚群,其特征是先天免疫信号通路明显下调。功能验证显示,在敏感模型中抑制干扰素信号可诱导耐药,而在耐药模型中激活干扰素信号、特别是干扰素β(IFN-β),可提高敏感性。IFN-β 与 KRAS 抑制剂(MRTX1133、HRS-4642 和 RMC-6236)联用,在内在耐药的胰腺癌中表现出协同抗肿瘤效应。机制上,持续的 MYC 活性与 KRAS 抑制敏感性减弱相关,并与干扰素信号受抑相关,提示其可能促进内在耐药。这些发现表明干扰素信号是 KRAS 靶向治疗反应的候选决定因素,并支持以干扰素为基础的联合方案作为内在耐药胰腺癌的潜在策略。
KRAS inhibitors (KRASi) are reshaping the treatment of aggressive tumors such as pancreatic ductal adenocarcinoma (PDAC), but it is appreciated that patients will eventually acquire resistance through multiple pathways. To avoid this outcome, there is much effort to identify combination therapies that take advantage of the 'window-of-opportunity' permitted from KRAS inhibition. Tumor cell-intrinsic targeting - as a result of KRASi - results in altered immune and stromal features within the PDAC tumor site that could allow for improved, non-KRAS-targeted, treatment efficacy. Qiang and colleagues investigate the potential of pairing KRASi with immunotherapy - here, an IL-21 mimic - for therapeutic benefit during this 'open window' phase of the KRASi-induced tumor debulking. IL-21 promotes a CD4 T cell response that requires both conventional type 2 dendritic cells (cDC2s) and interferon (IFN)-γ, but not direct tumor cell recognition via major histocompatibility complex (MHC). This work fits in a series of studies highlighting the ability to drive PDAC tumor rejection through cytokines derived from CD4, but not CD8, T cells. These findings highlight a divergence from more 'traditional' immunotherapeutic responses, where cytotoxic CD8 T cells have historically dominated tumor control. Identifying alternative paths towards targeting PDAC may be beneficial - and points towards cell types and modalities that could be leveraged for clinical benefit as the field identifies potential combinatorial partners for KRASi and more patients start receiving these drugs.
中文摘要:KRAS抑制剂(KRASi)正在改变胰腺导管腺癌(PDAC)等侵袭性肿瘤的治疗格局,但已知患者最终会通过多条途径产生耐药。为避免这一结果,许多工作致力于寻找联合疗法,以利用KRAS抑制带来的「机会窗口」。KRASi造成的肿瘤细胞内在靶向效应,会改变PDAC肿瘤部位的免疫与基质特征,从而可能提高非KRAS靶向治疗的疗效。Qiang及其同事探索将KRASi与免疫治疗——此处为IL-21模拟物——联用,在KRASi诱导肿瘤减负的「开放窗口」期获得治疗获益的潜力。IL-21促进CD4 T细胞应答,该应答需要经典2型树突状细胞(cDC2s)和干扰素(IFN)-γ,但不依赖肿瘤细胞通过主要组织相容性复合体(MHC)被直接识别。这项工作属于一系列研究,这些研究强调可通过源自CD4而非CD8 T细胞的细胞因子驱动PDAC肿瘤排斥。这些发现凸显了与更「传统」免疫治疗应答的差异,后者历史上以细胞毒性CD8 T细胞主导肿瘤控制。寻找靶向PDAC的替代路径可能有益,并指向可被用于临床获益的细胞类型和手段,因为该领域正在确定KRASi的潜在联合伙伴,且越来越多患者开始接受这些药物。
PBRM1 is an important subunit of the SWI/SNF complex, which broadly regulates gene transcription by chromatin remodeling. Genomic alterations of PBRM1 have been found in patients with pancreatic ductal adenocarcinoma (PDAC), but its molecular functions remain unclear. Clinical relevance of PBRM1 was analyzed by using human PDAC samples and public genomic datasets. Mice with concomitant pancreas-specific Pbrm1 deletion in Kras-driven genetic PDAC models were generated. Single-cell transcriptomics were performed to determine tumor phenotype and microenvironment reprogramming. Reduction of PBRM1 expression was observed in human PDAC tissues and correlated with poor prognosis and metastasis. Pbrm1 loss promoted ductal metaplasia and delayed epithelial recovery in mice with caerulein-induced pancreatic injury. In PDAC model with either mutant Kras alone or in combination with Trp53 mutation, lack of Pbrm1 markedly accelerated tumor development and progression. Bulk transcriptomics and scRNA-seq identified reprogramming of both tumor compartment with mesenchymal phenotype acquisition and stroma compartment with inflammatory cancer-associated fibroblasts (iCAFs) transformation. Mechanistically, Pbrm1 deletion induced Zeb1 upregulation through epigenetic chromatin remodeling, thereby enhancing epithelial-mesenchymal and basal-like subtype transition. These findings indicated a tumor-suppressing role of PBRM1 in PDAC. PBRM1-deficient PDAC constitutes a specific subgroup of patients with aggressive phenotype and prognostic significance.
中文摘要:PBRM1是SWI/SNF复合体的重要亚基,通过染色质重塑广泛调控基因转录。已在胰腺导管腺癌(PDAC)患者中发现PBRM1基因组改变,但其分子功能仍不清楚。利用人PDAC样本和公共基因组数据集分析PBRM1的临床相关性。在Kras驱动的遗传性PDAC模型中构建胰腺特异性Pbrm1缺失小鼠。采用单细胞转录组学确定肿瘤表型与微环境重编程。人PDAC组织中观察到PBRM1表达降低,并与不良预后和转移相关。Pbrm1缺失促进雨蛙素诱导胰腺损伤小鼠的导管化生并延迟上皮恢复。在仅携带突变Kras或联合Trp53突变的PDAC模型中,Pbrm1缺失显著加速肿瘤发生和进展。批量转录组学和scRNA-seq发现肿瘤区域获得间充质表型,间质区域转化为炎症性癌相关成纤维细胞(iCAFs)。机制上,Pbrm1缺失通过表观遗传染色质重塑诱导Zeb1上调,从而增强上皮-间充质转化和基底样亚型转换。这些发现表明PBRM1在PDAC中具有抑瘤作用。PBRM1缺陷型PDAC构成具有侵袭性表型和预后意义的一个特定患者亚组。
Failure of cancer vaccines in clinical trials has been linked to poor preclinical translatability, immunosuppressive tumor microenvironments (TMEs), suboptimal antigen delivery to antigen-presenting cells, limited human MHC antigenicity, and insufficiently safe immune adjuvants. Therefore, this study aimed to design an integrated cancer vaccine and evaluate its efficacy in a KPC orthotopic pancreatic cancer model containing the G12D mutation. A novel immune adjuvant, C-VAX, was developed from the natural Toll-like receptor 2/6 agonist UNE-C1 and covalently linked to a KRASG12D neoantigen and WNT5a, a tumor-associated antigen upregulated in resistant tumors. This integrated vaccine enhanced CD8⁺ T-cell infiltration and reduced α-SMA expression in the TME. The therapeutic effects were further enhanced following anti-PD-1 checkpoint blockade. These findings suggest that vaccines targeting tumor antigens and resistance-associated TME components may promote an immune-responsive TME in refractory cancers.
中文摘要:癌症疫苗在临床试验中的失败与以下因素有关:临床前可转化性差、免疫抑制性肿瘤微环境(TME)、抗原向抗原呈递细胞递送不理想、人MHC抗原性有限,以及免疫佐剂安全性不足。为此,本研究设计一种整合型癌症疫苗,并在携带G12D突变的KPC原位胰腺癌模型中评价其疗效。研究以天然Toll样受体2/6激动剂UNE-C1为基础开发新型免疫佐剂C-VAX,并将其与KRASG12D新抗原及WNT5a共价连接;WNT5a是在耐药肿瘤中上调的肿瘤相关抗原。该整合疫苗增强了CD8⁺ T细胞浸润,并降低TME中α-SMA表达。联合抗PD-1检查点阻断后,治疗效果进一步增强。上述结果提示,靶向肿瘤抗原及耐药相关TME组分的疫苗可能促进难治性癌症形成免疫应答型TME。
Chitinase-3-like-protein 1 (CHI3L1), a low-abundance protein in normal tissues, is markedly upregulated in the pancreatic tumor microenvironment (TME), where it promotes fibrosis and immune evasion. Spatial transcriptomics revealed enrichment of CHI3L1 at tumor-stroma interfaces, suggesting that cell-cell interactions regulate CHI3L1 expression. We employed 2D and 3D multicellular culture models, incorporating pancreatic cancer cells, macrophages, and pancreatic stellate cells (PSCs), to recapitulate TME-mediated CHI3L1 induction. Mechanistic insights were gained through secretome profiling, chromatin immunoprecipitation (ChIP), and methylation-specific PCR. The therapeutic potential of targeting identified axes was evaluated in an orthotopic pancreatic adenocarcinoma (PDAC) mouse model. We identified CCL2, CXCL10, and SPARC as key secreted mediators during tumor-stroma crosstalk that cooperatively induced CHI3L1 expression in cancer cells via activation of NF-κB and STAT3. Specifically, inflammatory cytokines within the TME recruited macrophages to induce CCL2, which, in concert with PSCs, enhances CXCL10 and SPARC secretion. Mechanistically, NF-κB directly bound the CHI3L1 promoter, while STAT3 reduced DNA methyltransferase 1 levels, leading to promoter hypomethylation and epigenetic activation of CHI3L1. Clinically, high CHI3L1 expression correlated with the upregulated stromal CCL2, CXCL10, and SPARC levels, and the combined four-marker signature was an independent prognostic factor for both overall and disease-free survival in multivariable analysis. In vivo, blockade of the upstream stromal pathways (CCR2/CXCR3/TGFβR1) coupled with CHI3L1 neutralization reduced tumor growth and remodeled the immunosuppressive microenvironment in immunocompetent PDAC models. Our findings uncover a cooperative multicellular signaling network that orchestrates CHI3L1 expression in cancer via transcriptional and epigenetic reprogramming. Disrupting these upstream stromal pathways concurrently with CHI3L1 neutralization was associated with reduced T-cell exhaustion, offering a promising combinatorial approach for PDAC immunotherapy.
中文摘要:几丁质酶-3样蛋白1(CHI3L1)在正常组织中低丰度,在胰腺肿瘤微环境(TME)中显著上调,促进纤维化和免疫逃逸。空间转录组显示CHI3L1在肿瘤-间质交界处富集,提示细胞间相互作用调控CHI3L1表达。我们采用二维和三维多细胞培养模型,纳入胰腺癌细胞、巨噬细胞和胰腺星状细胞(PSC),以重现TME介导的CHI3L1诱导。通过分泌组分析、染色质免疫沉淀(ChIP)和甲基化特异性PCR获得机制认识。在原位胰腺腺癌(PDAC)小鼠模型中评估靶向所发现通路的治疗潜力。我们确定CCL2、CXCL10和SPARC是肿瘤-间质交互过程中的关键分泌介质,它们通过激活NF-κB和STAT3协同诱导癌细胞CHI3L1表达。具体而言,TME中的炎性细胞因子招募巨噬细胞诱导CCL2,CCL2与PSC共同增强CXCL10和SPARC分泌。机制上,NF-κB直接结合CHI3L1启动子,STAT3降低DNA甲基转移酶1水平,导致启动子低甲基化和CHI3L1的表观遗传激活。临床上,高CHI3L1表达与间质CCL2、CXCL10和SPARC水平上调相关,四标志物联合特征在多变量分析中为总生存和无病生存的独立预后因素。体内,阻断上游间质通路(CCR2/CXCR3/TGFβR1)联合CHI3L1中和可减少免疫健全PDAC模型中的肿瘤生长并重塑免疫抑制微环境。这些发现揭示了一个协同的多细胞信号网络,通过转录和表观遗传重编程协调癌细胞CHI3L1表达。破坏这些上游间质通路并同时中和CHI3L1与T细胞耗竭减少相关,为PDAC免疫治疗提供有前景的联合策略。
Mucin-16 (MUC16) is overexpressed in >60% of pancreatic ductal adenocarcinoma (PDAC) cases and correlates with poor outcomes, yet its role in regulating tumor-immune interactions remains incompletely defined. Using KPC and KPC-MUC16 knockout (KPC-MUC16KO) genetically engineered and orthotopic mouse models, we show that loss of MUC16 markedly reduces tumor burden and reprograms the tumor microenvironment (TME) toward a less immunosuppressive state. MUC16 deficiency significantly decreased CD206+ and Ym1/2+ M2-like macrophages, increased the M1/M2 ratio, and improved survival. Cytokine profiling identified CCL2 and Serpin-E1 as MUC16- dependent secreted factors that promote macrophage recruitment and polarization; neutralization of these cytokines reduced macrophage migration in vitro. Bone marrow-derived macrophages (BMDM) exposed to MUC16-expressing tumor cells or conditioned media adopted a CD206+Arg1+ M2-like phenotype, whereas MUC16KO tumor signals favored inflammatory CD86+iNOS + M1-like polarization. Macrophage depletion using clodronate liposomes significantly impaired tumor growth in MUC16-competent tumors but had minimal effect in KPC-MUC16KO tumors, indicating dependence on macrophage-mediated immunosuppression in the former group. Spatial transcriptomics revealed a globally distinct TME in MUC16KO tumors, including enhanced antigen-presentation programs, increased complement activation, and fibroblast states skewed toward pro-inflammatory signaling. These findings establish MUC16 as a key orchestrator of macrophage-driven immunosuppression in PDAC and support therapeutic strategies combining MUC16-targeted interventions with TME-reprogramming approaches.
中文摘要:黏蛋白16(MUC16)在超过60%的胰腺导管腺癌(PDAC)病例中过表达,并与不良结局相关,但其在调控肿瘤-免疫相互作用中的作用仍未完全明确。利用KPC和KPC-MUC16敲除(KPC-MUC16KO)基因工程及原位小鼠模型,我们发现MUC16缺失显著降低肿瘤负荷,并将肿瘤微环境(TME)重编程为免疫抑制较弱的状态。MUC16缺陷显著减少CD206+和Ym1/2+ M2样巨噬细胞,提高M1/M2比值,并改善生存。细胞因子谱分析确定CCL2和Serpin-E1是MUC16依赖的分泌因子,可促进巨噬细胞募集和极化;中和这些细胞因子在体外减少巨噬细胞迁移。暴露于表达MUC16的肿瘤细胞或条件培养基的骨髓来源巨噬细胞(BMDM)获得CD206+Arg1+ M2样表型,而MUC16KO肿瘤信号促进炎症性CD86+iNOS+ M1样极化。使用氯膦酸盐脂质体清除巨噬细胞显著抑制MUC16正常表达肿瘤的生长,但对KPC-MUC16KO肿瘤影响很小,表明前者依赖巨噬细胞介导的免疫抑制。空间转录组学显示MUC16KO肿瘤的TME整体不同,包括抗原呈递程序增强、补体激活增加以及成纤维细胞状态偏向促炎信号。这些结果确立MUC16是PDAC中巨噬细胞驱动免疫抑制的关键协调者,并支持将MUC16靶向干预与TME重编程策略联合的治疗思路。
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint blockade (ICB), largely because of its immunosuppressive and T-cell-excluded tumor microenvironment. While inducing immunogenic cell death (ICD) offers a promising strategy to enhance tumor immunogenicity, redox-targeted ICD inducers with defined molecular targets remain limited in PDAC. Here, a functional screen of natural compounds identified erianin as a potent ICD inducer in PDAC. Erianin triggered canonical ICD hallmarks, including cell-surface calreticulin exposure, extracellular release of HMGB1 and ATP, thereby promoting dendritic-cell maturation, antigen cross-presentation and CD8+ T-cell activation. Target-engagement assays together with genetic perturbation supported glutathione reductase (GSR) as a functionally important erianin target. Erianin decreased the GSH/GSSG ratio, accompanied by increased oxidative stress and preferential activation of the PERK-eIF2α-ATF4-CHOP branch of the endoplasmic reticulum (ER) stress response. Mutational and rescue experiments identified ARG-233 as an important residue required for GSR-dependent protection against erianin-induced redox stress and ICD. In syngeneic PDAC models, erianin-treated tumor cells elicited protective antitumor immunity in a tumor-challenge setting, while a therapeutic regimen combining erianin with anti-PD-1 antibody suppressed tumor growth and was associated with increased dendritic-cell activation and enhanced cytotoxic CD8+ T-cell infiltration. These findings define a GSR-associated redox-immune axis that links glutathione metabolism to immunogenic ER stress and provide a rationale for combining erianin with PD-1 blockade in immunologically cold PDAC.
中文摘要:胰腺导管腺癌(PDAC)对免疫检查点阻断(ICB)反应不佳,主要因为其免疫抑制和T细胞排斥的肿瘤微环境。诱导免疫原性细胞死亡(ICD)是增强肿瘤免疫原性的有前景策略,但在PDAC中具有明确分子靶点的氧化还原靶向ICD诱导剂仍有限。对天然化合物的功能筛选发现毛兰素是PDAC中强效ICD诱导剂。毛兰素触发经典ICD标志,包括细胞表面钙网蛋白暴露、HMGB1和ATP胞外释放,从而促进树突状细胞成熟、抗原交叉呈递和CD8+ T细胞活化。靶点结合实验和遗传扰动支持谷胱甘肽还原酶(GSR)是毛兰素功能上重要的靶点。毛兰素降低GSH/GSSG比值,伴随氧化应激增加和内质网(ER)应激反应中PERK-eIF2α-ATF4-CHOP分支的优先激活。突变和回补实验确定ARG-233是GSR依赖性地抵御毛兰素诱导的氧化还原应激和ICD所需的重要残基。在同系PDAC模型中,毛兰素处理的肿瘤细胞在肿瘤挑战设置中引发保护性抗肿瘤免疫,而毛兰素与抗PD-1抗体联合的治疗方案抑制肿瘤生长,并与树突状细胞活化增加和细胞毒性CD8+ T细胞浸润增强相关。这些发现定义了连接谷胱甘肽代谢与免疫原性ER应激的GSR相关氧化还原-免疫轴,并为在免疫冷PDAC中联合毛兰素与PD-1阻断提供依据。
2胆管癌/胆道手术 (2篇)
临床研究 (1篇)
Evidence regarding the survival benefit of endobiliary radiofrequency ablation (RFA) in perihilar cholangiocarcinoma (CCA) remains limited. We evaluated the association between endobiliary RFA and overall survival in unresectable perihilar CCA, with a focus on the timing of exposure. This retrospective cohort study included 475 patients with unresectable perihilar CCA treated with endoscopic biliary drainage between 2015 and 2025 (90 with a single RFA session, 50 with two or more sessions). RFA was modeled as a time-dependent cumulative count (0, 1, or ≥2 sessions), with landmark analyses of subsequent 6-month mortality at baseline and 3, 6, 9, and 12 months. Sensitivity analyses adjusted for stent type and calendar year. RFA within 7 days of drainage was associated with lower 6-month mortality (adjusted hazard ratio [aHR] 0.34, 95%CI 0.16-0.70; P = 0.004). At the 3-month landmark, two or more sessions were associated with lower mortality (aHR 0.10, P = 0.02); no association was seen at later landmarks. These estimates were unchanged after adjustment for stent type and calendar year. Over the entire follow-up, two or more sessions were associated with lower mortality (aHR 0.59, P = 0.007), but this association was attenuated after adjustment for calendar year (aHR 0.77, P = 0.21). Recurrent biliary obstruction was more frequent after RFA (37.9% vs. 22.1%; P < 0.001), with the excess confined to nontumor causes. Endobiliary RFA was associated with improved survival in unresectable perihilar CCA, with the benefit concentrated in the first 3 months after biliary drainage, at the cost of more frequent nontumor-related biliary obstruction.
中文摘要:关于经胆道射频消融(RFA)在肝门部胆管癌(CCA)中生存获益的证据仍有限。本研究评估经胆道RFA与不可切除肝门部CCA总生存的关联,重点关注暴露时机。这项回顾性队列研究纳入2015年至2025年间接受内镜下胆道引流的475例不可切除肝门部CCA患者,其中90例接受单次RFA,50例接受两次或以上RFA。RFA以时间依赖性累积次数建模(0次、1次或≥2次),并在基线及3、6、9、12个月进行界标分析,评估其后6个月死亡率。敏感性分析校正支架类型和日历年份。引流后7天内行RFA与较低的6个月死亡率相关(校正风险比[aHR] 0.34,95%CI 0.16-0.70;P=0.004)。在3个月界标分析中,两次或以上RFA与较低死亡率相关(aHR 0.10,P=0.02);在更晚的界标分析中未见关联。校正支架类型和日历年份后,这些估计值未改变。在整个随访期间,两次或以上RFA与较低死亡率相关(aHR 0.59,P=0.007),但校正日历年份后该关联减弱(aHR 0.77,P=0.21)。RFA后复发性胆道梗阻更常见(37.9% vs. 22.1%;P<0.001),超出部分仅限于非肿瘤原因。经胆道RFA与不可切除肝门部CCA生存改善相关,获益集中在胆道引流后前3个月,代价是非肿瘤相关胆道梗阻更频繁。
基础研究 (1篇)
Biliary tract cancers (BTCs) comprise biologically heterogeneous subtypes with limited therapeutic options and variable responses to sorafenib. The biological basis underlying this variability remains unclear. In this study, we compared intrahepatic cholangiocarcinoma (iCCA) and gallbladder cancer (GBC) models under defined sorafenib exposure conditions using transcriptomic profiling, Seahorse-based mitochondrial stress assays, pharmacologic combination analysis, and patient-derived organoid models. In representative iCCA models, 1.25 μM sorafenib increased mitochondrial respiration and ATP production, whereas 10 μM sorafenib suppressed this respiratory adaptation. In contrast, representative GBC models exhibited persistent suppression of mitochondrial respiratory function across the tested conditions and did not display a comparable concentration-dependent shift. Integrated transcriptomic and pharmacologic analyses further identified mitochondrial Complex I as a treatment-relevant vulnerability under sorafenib exposure, with stronger combination interactions observed in iCCA models. These findings indicate that iCCA and GBC differ in their metabolic responses to sorafenib and highlight subtype-specific differences in mitochondrial adaptation under treatment stress.
中文摘要:胆道癌(BTCs)包含生物学异质性明显的亚型,治疗选择有限,对索拉非尼的反应不一。这种差异的生物学基础尚不清楚。本研究在设定的索拉非尼暴露条件下,采用转录组分析、基于Seahorse的线粒体压力检测、药物联合分析以及患者来源类器官模型,比较肝内胆管癌(iCCA)与胆囊癌(GBC)模型。代表性iCCA模型中,1.25 μM索拉非尼增强线粒体呼吸和ATP生成,10 μM索拉非尼则抑制这种呼吸适应。代表性GBC模型在受试条件下持续表现线粒体呼吸功能受抑,未见相近的浓度依赖性变化。转录组与药理学整合分析进一步发现线粒体复合体I是索拉非尼暴露下与治疗相关的脆弱点,iCCA模型中的联合作用更强。这些结果表明iCCA与GBC对索拉非尼的代谢反应不同,并提示治疗压力下线粒体适应存在亚型特异性差异。
3胰腺癌外科 (2篇)
基础研究 (2篇)
Patient-derived tumor organoids (PDTOs) are strongly influenced by culture medium. We compared OncoPro™ (OP) Tumoroid Culture medium with conventional Wnt/R-spondin/noggin (Wnt) medium. This recently developed OP medium offers a standardized, serum-free alternative to Wnt-based formulations. We compared OP and Wnt media across 36 PDTO lines from various malignancies (colorectal, pancreatic, breast, lung, gastric, gastroesophageal junction, biliary head and neck and unknown primary), assessing establishment success. Selected PDTO models were subjected to downstream characterization, including morphological assessment and bulk transcriptomic profiling with comparison to public single-cell RNA sequencing reference datasets (n = 11), whole-exome sequencing (WES) (n = 9), and pharmacological response profiling to a 33-drug panel (n = 3). Adaptation from Wnt medium to OP succeeded in 83.3% (15/18), whereas de novo establishment favored Wnt (33.3% vs 11.1%). Key oncogenic driver alterations were retained across matched organoid cultures, supporting preservation of tumor-relevant genomic features. Transcriptomic profiling confirmed preserved tumor-identity across media, while revealing different epithelial state programs: Wnt upregulated proliferation/stemness-associated genes (e.g. LGR5) and OP enriched adhesion-associated genes and inflammatory/TGF-β programs. In scRNA databases OP signatures preferentially mapped to malignant epithelial compartments in pancreatic cancer, whereas Wnt signatures were linked to non-malignant epithelium. Similarly, in colon cancer OP signature mapped predominantly to the malignant epithelial compartments. Drug (n = 33) screening in pancreatic- and colorectal cancer PDTOs (n = 3) demonstrated consistent medium-dependent shifts: Wnt-grown PDTOs were globally more sensitive in the screened subset, particularly to MAPK-axis inhibitors and apoptosis-sensitizers, while OP-grown PDTOs exhibited relative resistance. Culture medium composition is a key determinant of PDTO phenotype, transcriptome and drug sensitivity. Wnt medium was associated with drug-sensitive states, whereas OP medium was associated with adhesion- and inflammatory-related programs, relative resistance in the screened subset of 33 drugs and closer alignment with malignant epithelial programs in the analyzed pancreatic / colorectal cancer single-cell atlases.
中文摘要:患者来源肿瘤类器官(PDTO)受培养基影响明显。研究比较OncoPro™(OP)Tumoroid Culture培养基与常规Wnt/R-spondin/noggin(Wnt)培养基;OP是近期开发的标准化无血清替代方案。研究在36株来自多种恶性肿瘤的PDTO中比较OP与Wnt的建立成功率,肿瘤类型包括结直肠癌、胰腺癌、乳腺癌、肺癌、胃癌、胃食管结合部癌、胆道癌、头颈癌和原发灶不明癌。选取部分PDTO模型做下游表征,包括形态学评估、批量转录组分析并与公共单细胞RNA测序参考数据集(n=11)比较、全外显子测序(WES,n=9)以及对33种药物panel的药理反应分析(n=3)。由Wnt培养基适应至OP的成功率为83.3%(15/18),从头建立则更倾向Wnt(33.3%对11.1%)。配对类器官培养保留关键致癌驱动基因改变,支持肿瘤相关基因组特征得以维持。转录组分析显示不同培养基下肿瘤身份得以保留,同时呈现不同的上皮状态程序:Wnt上调增殖/干性相关基因(如LGR5),OP富集黏附相关基因及炎症/TGF-β程序。在单细胞RNA数据库中,胰腺癌的OP特征主要映射至恶性上皮区室,Wnt特征与非恶性上皮相关;结肠癌中OP特征也主要映射至恶性上皮区室。对胰腺癌和结直肠癌PDTO(n=3)进行33种药物筛选显示一致的培养基依赖性变化:在所筛药物子集中,Wnt培养的PDTO总体更敏感,尤其对MAPK轴抑制剂和凋亡增敏剂,OP培养的PDTO则相对耐药。培养基组成是PDTO表型、转录组和药物敏感性的关键决定因素。Wnt培养基与药物敏感状态相关,OP培养基与黏附及炎症相关程序、33种药物受筛子集中的相对耐药相关,并在所分析的胰腺癌/结直肠癌单细胞图谱中更接近恶性上皮程序。
The acidic microenvironment in solid tumors is not merely a metabolic byproduct of the Warburg effect but actively promotes disease aggressiveness and treatment failure. Tumor alkalization therapy, which aims to neutralize or alkalinize the TME, has therefore emerged as a promising adjunct to conventional cancer treatments. In this study, we fabricated both SERS nanosensors and microsensors for parallel spatiotemporal monitoring of intracellular pH (pHi) and extracellular pH (pHe) within tumor spheroids derived from three human cancer cell lines: lung adenocarcinoma (H1975), pancreatic cancer (SW1990), and colorectal cancer (SW480). Over a 7-day culture period, distinct pHi and pHe profiles were observed among the different cell types. We then examined the pH modulation elicited by administration of sodium bicarbonate (NaHCO3), a clinically employed alkaline agent. Exposure to 75 mM NaHCO3 for 24 h induced a marked elevation of pHe (∼0.78 units) and a modest increment in pHi (∼0.37 units). This integrated nanosensor-microsensor system, which leverages the size effect for precise spatial localization, offers a versatile approach for elucidating the complex interactions within the tumor microenvironment and helps optimize pH-modulating cancer therapies.
中文摘要:实体瘤的酸性微环境并非Warburg效应单纯的代谢副产物,还会主动促进疾病侵袭性并导致治疗失败。肿瘤碱化治疗旨在中和或碱化肿瘤微环境,因而成为常规癌症治疗的一种有前景的辅助手段。本研究制备了SERS纳米传感器和微传感器,对来源于三种人癌细胞系的肿瘤球体内部细胞内pH(pHi)与细胞外pH(pHe)进行平行时空监测,细胞系包括肺腺癌H1975、胰腺癌SW1990和结直肠癌SW480。在7天培养期内,不同细胞类型呈现出不同的pHi和pHe变化特征。随后,我们考察了临床使用的碱性药物碳酸氢钠(NaHCO3)引起的pH调节。暴露于75 mM NaHCO3 24小时使pHe显著升高(约0.78单位),pHi仅小幅增加(约0.37单位)。这一整合纳米传感器与微传感器的系统利用尺寸效应实现精确空间定位,为阐明肿瘤微环境中的复杂相互作用提供了通用方法,并有助于优化pH调节型癌症治疗。
4多癌种统计 (1篇)
临床研究 (1篇)
Cancer is the second leading cause of death worldwide and disproportionately affects older adults. As population ageing accelerates, the global cancer burden among older adults continues to increase. This study systematically evaluated the latest global cancer burden and its epidemiological characteristics among older adults. Data on the incidence and mortality of 33 malignancies, excluding non-melanoma skin cancer, among adults aged 65 + were extracted from the Global Cancer Observatory (GLOBOCAN) 2024 and Global Burden of Disease Study (GBD) 2023 databases and stratified by age, sex, region, and Human Development Index (HDI). Age-standardized incidence and mortality rates (ASIR and ASMR) were calculated. Annual percentage changes (APC) were used to characterize temporal trends. Decomposition analysis was performed to quantify the contributions of population growth, population aging, and epidemiological changes. Demographic projection methods and generalized additive model (GAM) were applied to forecast the cancer burden through 2050. In 2024, there were 9,966,392 new cancer cases and 6,001,290 cancer deaths among older adults worldwide, accounting for 51.11% and 61.84%, respectively, of all-age totals. Lung, colorectal, stomach, liver, and prostate cancers were leading causes of death. Incidence and mortality were higher in men and increased with age. The Western Pacific Region had the largest burden, whereas Europe Region had the highest ASIR. ASIR correlated positively with HDI (rs = 0.771), while mortality-to-incidence ratio (MIR) correlated negatively (rs = -0.825). From 2000 to 2023, ASIR and ASMR declined, although burden increased, primarily driven by population growth; pancreatic cancer exhibited the most rapid increase. Tobacco use remained the leading risk factor for mortality, while metabolic risks rose in importance. Under a demographic scenario assuming constant 2024 age-specific rates and changes only in population size and age structure, new cancer cases and deaths among older adults are projected to reach approximately 19.8 million and 12.5 million by 2050, roughly double the 2024 figures, with the largest increase in the Eastern Mediterranean region. Cancer burden in older adults is substantial, varying by sex, age, region, and development level. Precision prevention and control are urgently needed, particularly in low- and middle-income regions. REGISTRY AND THE REGISTRATION NO. N/A.
中文摘要:癌症是全球第二大死因,对老年人的影响尤为突出。人口老龄化加快,全球老年人癌症负担持续上升。该研究系统评估了老年人最新的全球癌症负担及其流行病学特征。研究从全球癌症观察站(GLOBOCAN)2024和全球疾病负担研究(GBD)2023数据库中提取65岁及以上成人33种恶性肿瘤(不包括非黑色素瘤皮肤癌)的发病和死亡数据,并按年龄、性别、地区及人类发展指数(HDI)分层。计算年龄标化发病率和死亡率(ASIR和ASMR),用年度百分比变化(APC)描述时间趋势。分解分析用于量化人口增长、人口老龄化和流行病学变化各自的贡献。采用人口学预测方法和广义相加模型(GAM)预测至2050年的癌症负担。2024年,全球老年人新发癌症9,966,392例,癌症死亡6,001,290例,分别占全年龄组的51.11%和61.84%。肺癌、结直肠癌、胃癌、肝癌和前列腺癌是主要死因。男性和高龄人群的发病率和死亡率更高。西太平洋地区负担最大,欧洲地区ASIR最高。ASIR与HDI呈正相关(rs=0.771),死亡发病比(MIR)与HDI呈负相关(rs=-0.825)。2000年至2023年,ASIR和ASMR下降,但负担上升,主要由人口增长驱动;胰腺癌增幅最快。吸烟仍是死亡的首位危险因素,代谢风险的重要性上升。在假定2024年年龄别率不变、仅人口规模和年龄结构变化的人口学情景下,预计到2050年老年人新发癌症病例和死亡将分别达到约1980万例和1250万例,约为2024年数字的两倍,东地中海地区增幅最大。老年人癌症负担沉重,并随性别、年龄、地区和发展水平而变化。迫切需要精准防控,尤其是在中低收入地区。注册信息与注册号:不适用。
5胰腺癌/胰十二指肠切除 (1篇)
基础研究 (1篇)
Pancreatic ductal adenocarcinoma (PDAC) is often burdened by cachexia, a metabolic disorder characterized by extensive and severe adipose tissue wasting and muscle atrophy that shortens life expectancy. While adipose depletion frequently coincides with myopathy, the precise molecular mediators by which remodeled adipocytes drive muscle atrophy remain largely undefined. Here, we delineated a pathogenic 'feed-forward' axis wherein tumor-derived inflammatory stimuli (IL-6/TNF-α) drove adipocytes to secrete extracellular vesicles (EVs) enriched with miR-221-3p. Genetic tracing confirmed that these EVs circulated systemically and were actively taken up by skeletal muscle. At the molecular level, EV-delivered miR-221-3p repressed IRS1, leading to the collapse of the PI3K-AKT survival cascade. Consequently, this inhibition triggered severe metabolic dysregulation by coupling impaired GLUT4-dependent glucose transport with heightened ubiquitin-proteasome activity, ultimately culminating in muscle atrophy. Silencing miR-221-3p via AAV-sponges or antagomirs conferred significant protection against muscle wasting and functional decline in cachectic mice. Importantly, high levels of circulating EV-miR-221-3p not only marked the presence of cachexia but were also significantly associated with reduced overall survival in PDAC patients. Collectively, our findings uncover a pathogenic adipose-to-muscle axis mediated by EV-miR-221-3p, offering a novel therapeutic target and a promising non-invasive biomarker for PDAC-associated cachexia.
中文摘要:胰腺导管腺癌(PDAC)常伴随恶病质,这是一种以广泛而严重的脂肪组织消耗与肌肉萎缩为特征的代谢紊乱,会缩短生存期。脂肪耗竭常与肌病同时出现,但重塑后的脂肪细胞驱动肌肉萎缩的确切分子介导物大多尚未明确。我们描绘了一条致病性「前馈」轴:肿瘤来源的炎症刺激(IL-6/TNF-α)促使脂肪细胞分泌富含 miR-221-3p 的细胞外囊泡(EV)。遗传示踪证实这些 EV 进入体循环并被骨骼肌主动摄取。在分子层面,EV 递送的 miR-221-3p 抑制 IRS1,导致 PI3K-AKT 生存级联崩溃。由此引发的抑制把受损的 GLUT4 依赖性葡萄糖转运与增强的泛素-蛋白酶体活性耦联,造成严重代谢失调,最终导致肌肉萎缩。通过 AAV-sponge 或 antagomir 沉默 miR-221-3p,可显著保护恶病质小鼠免于肌肉消耗与功能减退。循环 EV-miR-221-3p 水平升高不仅提示恶病质的存在,还与 PDAC 患者总生存期缩短显著相关。这些结果揭示了一条由 EV-miR-221-3p 介导的致病性脂肪-肌肉轴,为 PDAC 相关恶病质提供了新的治疗靶点与有前景的无创生物标志物。
6肝切除/腹腔镜 (1篇)
临床研究 (1篇)
Randomized clinical trials (RCTs) have compared laparoscopic liver resection (LLR) and open liver resection (OLR) for colorectal liver metastases (CRLM); however, long-term outcomes and subgroup effects have not been comprehensively evaluated. To compare postoperative and long-term oncologic outcomes after LLR versus OLR for CRLM using individual participant data from RCTs. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from database inception through March 2025 for RCTs comparing LLR and OLR for CRLM. Eligible studies were RCTs comparing LLR and OLR for CRLM. Individual participant data, including unpublished data, were obtained from trial investigators of all 4 published RCTs. Analyses used a modified intention-to-treat approach and 1-stage individual participant data meta-analysis (IPDMA) with trial-adjusted regression models and g-computation to estimate standardized treatment effects across outcomes, with 95% CIs obtained by nonparametric bootstrap resampling. Prespecified subgroup analyses assessed heterogeneity of treatment effect for the primary outcome. A total of 761 patients were included (laparoscopic, n = 384; open, n = 377). Postoperative morbidity was lower in patients assigned to laparoscopic surgery compared with open surgery (19% vs. 27%). Among patients who received preoperative systemic therapy, morbidity did not differ between groups (25% vs. 24%). Ninety-day mortality was 1.8% after LLR and 0.8% after OLR. After a median follow-up of 93 months, overall survival and disease-free survival did not differ between groups. Analyses were limited to variables available across all studies. In this IPDMA of all published RCTs in the field, LLR for CRLM was associated with lower postoperative morbidity than OLR, with similar long-term oncologic outcomes. None. (PROSPERO: CRD42024502655).
中文摘要:随机临床试验(RCT)已比较腹腔镜肝切除(LLR)与开腹肝切除(OLR)治疗结直肠癌肝转移(CRLM)的效果,但长期结局与亚组效应尚未得到全面评价。本研究旨在利用RCT的个体受试者数据,比较CRLM患者接受LLR与OLR的术后结局与长期肿瘤学结局。检索PubMed、Embase与Cochrane对照试验中心注册库自建库至2025年3月的资料,纳入比较LLR与OLR治疗CRLM的RCT。从4项已发表RCT的研究者处获取个体受试者数据,包括未发表数据。分析采用改良意向性治疗原则与一阶段个体受试者数据荟萃分析(IPDMA),使用按试验校正的回归模型与g计算法估计各结局的标准化治疗效应,95%CI通过非参数自助重抽样获得。预设亚组分析用于评估主要结局的治疗效应异质性。共纳入761例患者(腹腔镜组384例,开腹组377例)。分配至腹腔镜手术的患者术后并发症发生率低于开腹手术(19%对27%)。在术前接受全身治疗的患者中,两组并发症发生率无差异(25%对24%)。LLR后90天死亡率为1.8%,OLR后为0.8%。中位随访93个月后,两组总生存与无病生存无差异。分析限于各研究均具备的变量。在这项纳入该领域全部已发表RCT的IPDMA中,CRLM的LLR相较OLR术后并发症发生率更低,长期肿瘤学结局相似。无。(PROSPERO:CRD42024502655)